5-2-06

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/751543-Conf. #2403 Filing Date **TRANSMITTAL** January 5, 2004 **FORM** First Named Inventor M. Merle ELLOSO Art Unit 1617 (to be used for all correspondence after initial filing) **Examiner Name** S. Kantamneni Attorney Docket Number Total Number of Pages in This Submission 0036119.00161US2/AM101281

ENCLOSURES (Check all that apply)						
Fee Trans	mittal Form	Drawing(s)		After Allowance Communication to TC		
Fee	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Repty Brief)		
After	r Final	Petition to Convert to a Provisional Application		Proprietary Information		
Affid	lavits/declaration(s)	Power of Attorney, Revocate Change of Correspondence		Status Letter		
Extension	of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):		
Express Al	bandonment Request	Request for Refund		Return Receipt Postcard		
	ntal Information Statement	CD, Number of CD(s)				
Certified C Document	opy of Priority (s)	Landscape Table on CD				
	lissing Parts/ Application	Remarks				
Reply to Missing Parts under 37 CFR 1.52 or 1.53						
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP					
Signature	gnature Will Superko					
Printed name						
Date	May 1, 2006		Reg. No.	39,850		
	<u> </u>		<u> </u>			

		 	
Express Mail Label No. EV621477401US	Dated: May 1, 2006	 	

Docket No.: 0036119.00161US2/AM101281

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

M. Merle ELLOSO et al.

Confirmation No.:

2403

Application No.:

10/751543

Art Unit:

1617

Filed:

January 5, 2004

Examiner:

S. Kantamneni

Title:

USE OF ESTROGEN RECEPTOR ALPHA MODULATORS FOR THE

TREATMENT OF MULTIPLE SCLEROSIS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: May 1, 2006

Colleen Superko

Registration No.: 39,850 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile)

MAY 0 1 2006 W

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/751543-Conf. #2403	
IN	FORMATIC	ON DIS	CLOSURE	Filing Date	January 5, 2004	
S	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	M. Merle ELLOSO	
				Art Unit	1617	
				Examiner Name	Kantamneni	
Sheet	1	of	1	Attomey Docket Number	0036119.00161US2/AM101281	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document					
	ВА	EP 0 240 131	10-07-1987	IMPERIAL INDUSTRIES PLC		Г			
	BB	EP 0 667 768	03-03-1999	NIPPON KAYAKU		Г			
]	KABUSHIKI KAISHA et al.					
	BC	EP 0 792 640	09-03-1997	PFIZER INC					
	BD	EP 0 792 641	09-03-1997	PFIZER INC					
	BE	EP 0 792 642	09-03-1997	PFIZER INC					
	BF	EP 1 120 114	08-01-2001	PFIZER PRODUCTS INC					
	BG	WO 93/22685	11-11-1993	THE GOVERNMENT OF THE					
				UNITED STATES OF		ĺ			
				AMERICA as represented by		ĺ			
	ļ			the DEPARTMENT OF					
				HEALTH AND HUMAN		ĺ			
				SERVICES					
	ВН	WO 94/09764	05-11-1994	NIPPON KAYAKU					
				KABUSHIKI KAISHA et al.		1			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nich of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	CA	BADGER et al., "Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis," Journal of Pharmacology and Experimental Therapeutics, (1999), pp. 1380-1386, Vol. 291, No. 3.					
	СВ	GRANIGER et al., "Tamoxifen: Teaching an Old Drug New Tricks?" Nature Medicine, (1996), pp. 381-385, Vol. 2, No. 4.					
	CC	MARKUS et al., "Tamoxifen inhibits disease expression in murine experimental autoimmune encephalomyelitis," Neurology, (2000), pp. A61, Vol. 54, No. 7.					
	CD	XP002372596, DATABASE WPI, Abstract, (1998)					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	1

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.